Record Revenue and Growth
Total revenue for the first quarter of 2025 was $124 million, representing a 14% growth compared to the first quarter of 2024.
Significant Increase in Profitability
Adjusted EBITDA for the first quarter was $9 million, an improvement of more than 200% from the first quarter of 2024.
Strong Performance in Appendage Management
Worldwide appendage management revenue grew 19%, with 23% growth in open AtriClip devices and 7% growth in MIS appendage management devices.
Successful Product Launches
The AtriClip Flex Mini and Pro Mini devices received positive feedback, contributing significantly to the revenue of the appendage management franchise.
Pain Management Franchise Growth
The pain management franchise saw an acceleration in growth to 39% in the first quarter, driven by the adoption of cryoSPHERE MAX and cryoSPHERE+ probes.
International Revenue Growth
International revenue increased by 20.8% on a reported basis and 23.9% on a constant currency basis compared to the first quarter of 2024.